| Drug Name |
Avatrombopag |
| Drug ID |
BADD_D02497 |
| Description |
Avatrombopag (_Doptelet_), is an orally administered, small-molecule thrombopoietin receptor (c-Mpl) agonist which increases platelet number, but not platelet activation [A33097], [L2824]. This decreases the need for blood transfusions [L2824].
Patients with thrombocytopenia and chronic liver disease (leading to thrombocytopenia) often require platelet transfusions before surgical procedures to decrease the risk of bleeding [A33095]. Thrombocytopenia (or decreased numbers of platelets) is a common complication in patients suffering from chronic liver disease, either as an immediate result of liver disease or a consequence of interferon-based antiviral therapy [F95].
Avatrombopag was approved by the FDA on May 21, 2018 for thrombocytopenia (low platelets) in adults with chronic liver disease who are scheduled to undergo a procedure [L2931]. It is administered orally as _avatrombopag maleate_, its salt form [L2927].
_Doptelet_ (Avatrombopag) is the first orally administered treatment option for patients with chronic liver disease, allowing a large population of patients to avoid a platelet transfusion before a procedure by increasing platelet counts to the optimal level of greater or equal to 50,000 per microliter [L2932]. |
| Indications and Usage |
Indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure [FDA label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
B02BX08 |
| DrugBank ID |
DB11995
|
| KEGG ID |
D10306
|
| MeSH ID |
C533238
|
| PubChem ID |
9852519
|
| TTD Drug ID |
D0W1DI
|
| NDC Product Code |
Not Available |
| UNII |
3H8GSZ4SQL
|
| Synonyms |
avatrombopag | Doptelet | AKR 501 | AKR501 | AKR-501 | YM 477 | YM477 | YM-477 | E5501 compound | 1-(3-chloro-5-((4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)-2-pyridyl)piperidine-4-carboxylic acid |
